DrugBiological
Ragifilimab clinical trials
Also written INCAGN01876.
- studies test it
- 5
- open now
- 0
- in phase 3
- 0
- first study started
- 2016
How studies write it
Studies that test it under each name
Development codes
- INCAGN01876
- 5
Studies by the year they started
5 studies that test it; most in 2017 (2)
| Year | Studies |
|---|---|
| 2016 | 1 |
| 2017 | 2 |
| 2021 | 1 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 3 · Other 2
Incyte Biosciences International Sàrl (3) · Providence Health & Services (1) · European Organisation for Research and Treatment of Cancer - EORTC (1)
Often tested with
Tested in the same studies.
Afatinib (1) · Palbociclib (1) · Monalizumab (1) · Durvalumab (1) · Niraparib (1)
Studies
Open first, then newest update. How each study uses ragifilimab is read from its arms, and is right about nine times in ten.
Testing it · 5
- Phase Ib Trial of Multivalent Autophagosome Vaccine With or Without GITR Agonist, With Anti-PD-1 Immunotherapy in HNSCCActive, not recruitingPhase 1Providence Health & ServicesNCT04470024Written as INCAGN01876
- Biomarker-based Study in R/M SCCHNActive, not recruitingPhase 2European Organisation for Research and Treatment of Cancer - EORTCNCT03088059Written as INCAGN01876
- INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaWithdrawnPhase 2Incyte Biosciences International SàrlNCT05359692Written as INCAGN01876
- INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic MalignanciesTerminatedPhase 1/2Incyte Biosciences International SàrlNCT03277352Written as INCAGN01876
- A Study of INCAGN01876 in Participants With Advanced or Metastatic Solid TumorsCompletedPhase 1/2Incyte Biosciences International SàrlNCT02697591Written as INCAGN01876
Given in every arm · 2 — ragifilimab is usual care beside what is tested
- Anti-GITR/Anti-PD1/Stereotactic Radiosurgery, in Recurrent GlioblastomaActive, not recruitingPhase 2University of PennsylvaniaNCT04225039Written as INCAGN01876
- Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic MalignanciesCompletedPhase 1/2Incyte Biosciences International SàrlNCT03126110Written as INCAGN01876
Codes
What other systems call ragifilimab · ClinicalTrials.gg INT017448
- UNII (FDA) O440IW9NHNRAGIFILIMABOne source FDA
- NCI Thesaurus C126643RagifilimabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | O440IW9NHN | RAGIFILIMAB | One source FDA |
| NCI Thesaurus | C126643 | Ragifilimab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.